G protein-coupled receptor GPR160 is associated with apoptosis and cell cycle arrest of prostate cancer cells

Oncotarget

Volumn 7, Issue 11, 2016, Pages 12823-12839

  Zhou, Caihong ^a   Dai, Xinchuan ^a   Chen, Yi ^a   Shen, Yanyan ^a   Lei, Saifei ^a   Xiao, Ting ^a   Bartfai, Tamas ^b   Ding, Jian ^a   Wang, Ming Wei ^a,c  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle arrest; GPR160; Orphan g protein coupled receptor; Prostate cancer

Indexed keywords

CYTOKINE; G PROTEIN COUPLED RECEPTOR; PROTEIN GPR160; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; GPR160 PROTEIN, HUMAN; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CONTROLLED STUDY; CYTOSKELETON; DIFFERENTIALLY EXPRESSED GENE; DISEASE ASSOCIATION; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; GPR160 GENE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN FUNCTION; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; TRANSCRIPTOME;

EID: 84962920777     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7313     Document Type: Article

References (45)

1. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002; 3:639-650.
2. Bartfai T, Lees VG. Drug Discovery: from Bedside to Wall Street: Elsevier Academic Press.
3. Rask-Andersen M, Almen MS, Schioth HB. Trends in the exploitation of novel drug targets. Nat Rev Drug Discov. 2011; 10:579-590.
4. Heng BC, Aubel D, Fussenegger M. An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases. Biotechnol Adv. 2013; 31:1676-1694.
5. Tang XL, Wang Y, Li DL, Luo J, Liu MY. Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets. Acta Pharmacol Sin. 2012; 33:363-371.
6. Young D, Waitches G, Birchmeier C, Fasano O, Wigler M. Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell. 1986; 45:711-719.
7. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007; 7:79-94.
8. O'Hayre M, Degese MS, Gutkind JS. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr Opin Cell Biol. 2014; 27:126-135.
9. O'Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, Gutkind JS. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer. 2013; 13:412-424.
10. GPR160 gene. http://www.genecards.org/. 2015.
11. Regard JB, Sato IT, Coughlin SR. Anatomical profiling of G protein-coupled receptor expression. Cell. 2008; 135:561-571.
12. GPR160. http://www.ebi.ac.uk/gxa/. 2015.
13. Schlomm T, Luebke AM, Sultmann H, Hellwinkel OJ, Sauer U, Poustka A, David KA, Chun FK, Haese A, Graefen M, Erbersdobler A, Huland H. Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis. Int J Oncol. 2005; 27:713-720.
14. Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood. 2007; 109:1720-1727.
15. Sheu JJ, Lee CH, Ko JY, Tsao GS, Wu CC, Fang CY, Tsai FJ, Hua CH, Chen CL, Chen JY. Chromosome 3p12.3-p14.2 and 3q26.2-q26.32 are genomic markers for prognosis of advanced nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2009; 18:2709-2716.
16. Qin Y, Verdegaal EM, Siderius M, Bebelman JP, Smit MJ, Leurs R, Willemze R, Tensen CP, Osanto S. Quantitative expression profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target. Pigment Cell Melanoma Res. 2011; 24:207-218.
17. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordonez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010; 463:191-196.
18. Izumiya M, Tsuchiya N, Okamoto K, Nakagama H. Systematic exploration of cancer-associated microRNA through functional screening assays. Cancer Sci. 2011; 102:1615-1621.
19. Lee JE, Hong EJ, Nam HY, Kim JW, Han BG, Jeon JP. MicroRNA signatures associated with immortalization of EBV-transformed lymphoblastoid cell lines and their clinical traits. Cell Prolif. 2011; 44:59-66.
20. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61:1079-1092.
21. Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA, Zou Z, Srikantan V, Augustus M, Roschke V, Carter K, McLeod DG, Moul JW, et al. PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res. 2000; 60:6568-6572.
22. Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer Prostatic Dis. 2006; 9:56-61.
23. Taub JS, Guo R, Leeb-Lundberg LM, Madden JF, Daaka Y. Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res. 2003; 63:2037-2041.
24. Pi M, Parrill AL, Quarles LD. GPRC6A mediates the non-genomic effects of steroids. J Biol Chem. 2010; 285:39953-39964.
25. Pi M, Quarles LD. GPRC6A regulates prostate cancer progression. Prostate. 2012; 72:399-409.
26. Don-Salu-Hewage AS, Chan SY, McAndrews KM, Chetram MA, Dawson MR, Bethea DA, Hinton CV. Cysteine (C)-x-C receptor 4undergoes transportin 1-dependent nuclear localization and remains functional at the nucleus of metastatic prostate cancer cells. PLoS One. 2013; 8:e57194.
27. Kasina S, Macoska JA. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol. 2012; 351:249-263.
28. GPR160. http://www.guidetopharmacology.org. 2015.
29. Derwent Innovations Index. http://thomsonreuters.com/. 2015.
30. GPR160-Metastatic prostate cancer (HG-U95B). http://www.ncbi.nlm.nih.gov/geoprofiles/. 2015.
31. Rhim JS, Webber MM, Bello D, Lee MS, Arnstein P, Chen LS, Jay G. Stepwise immortalization and transformation of adult human prostate epithelial cells by a combination of HPV-18 and v-Ki-ras. Proc Natl Acad Sci U S A. 1994; 91:11874-11878.
32. Gobeil S, Boucher CC, Nadeau D, Poirier GG. Characterization of the necrotic cleavage of poly (ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. Cell Death Differ. 2001; 8:588-594.
33. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999; 15:269-290.
34. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev. 2009; 227:75-86.
35. Li S, Huang S, Peng SB. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol. 2005; 27:1329-1339.
36. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene. 2008; 27:6194-6206.
37. Veeranki S. Role of inflammasomes and their regulators in prostate cancer initiation, progression and metastasis. Cell Mol Biol Lett. 2013; 18:355-367.
38. Winter RN, Kramer A, Borkowski A, Kyprianou N. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. 2001; 61:1227-1232.
39. Winter RN, Rhee JG, Kyprianou N. Caspase-1 enhances the apoptotic response of prostate cancer cells to ionizing radiation. Anticancer Res. 2004; 24:1377-1386.
40. Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate. 2000; 42:1-7.
41. Pencik J, Wiebringhaus R, Susani M, Culig Z, Kenner L. L-6/STAT3/ARF: the guardians of senescence, cancer progression and metastasis in prostate cancer. Swiss Med Wkly. 2015; 145:w14215.
42. Zhou C, Wu G, Feng Y, Li Q, Su H, Mais DE, Zhu Y, Li N, Deng Y, Yang D, Wang MW. Discovery and biological characterization of a novel series of androgen receptor modulators. Br J Pharmacol. 2008; 154:440-450.
43. Zhang ZY, Zhu YH, Zhou CH, Liu Q, Lu HL, Ge YJ, Wang MW. Development of beta-amino-carbonyl compounds as androgen receptor antagonists. Acta Pharmacol Sin. 2014; 35:664-673.
44. Kohutyuk O, Towfic F, Greenlee HW, Honavar V. BioNetwork Bench: Database and Software for Storage, Query, and Analysis of Gene and Protein Networks. Bioinform Biol Insights. 2012; 6:235-246.
45. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13:2498-2504.